- Home
- ZLAB vs RCKT Comparison
ZLAB vs RCKT Comparison
Compare ZLAB & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- RCKT
- Stock Information
- Founded
- ZLAB 2013
- RCKT 1999
- Country
- ZLAB China
- RCKT United States
- Employees
- ZLAB N/A
- RCKT N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- ZLAB Health Care
- RCKT Health Care
- Exchange
- ZLAB Nasdaq
- RCKT Nasdaq
- Market Cap
- ZLAB 3.6B
- RCKT 326.4M
- IPO Year
- ZLAB 2017
- RCKT N/A
- Fundamental
- Price
- ZLAB $36.40
- RCKT $2.95
- Analyst Decision
- ZLAB Buy
- RCKT Buy
- Analyst Count
- ZLAB 5
- RCKT 13
- Target Price
- ZLAB $54.28
- RCKT $18.50
- AVG Volume (30 Days)
- ZLAB 886.5K
- RCKT 4.3M
- Earning Date
- ZLAB 08-05-2025
- RCKT 08-04-2025
- Dividend Yield
- ZLAB N/A
- RCKT N/A
- EPS Growth
- ZLAB N/A
- RCKT N/A
- EPS
- ZLAB N/A
- RCKT N/A
- Revenue
- ZLAB $418,326,000.00
- RCKT N/A
- Revenue This Year
- ZLAB $44.07
- RCKT N/A
- Revenue Next Year
- ZLAB $49.13
- RCKT N/A
- P/E Ratio
- ZLAB N/A
- RCKT N/A
- Revenue Growth
- ZLAB 43.72
- RCKT N/A
- 52 Week Low
- ZLAB $16.01
- RCKT $2.19
- 52 Week High
- ZLAB $44.34
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- ZLAB 52.67
- RCKT 41.69
- Support Level
- ZLAB $34.79
- RCKT $2.40
- Resistance Level
- ZLAB $36.73
- RCKT $2.70
- Average True Range (ATR)
- ZLAB 1.23
- RCKT 0.21
- MACD
- ZLAB -0.46
- RCKT 0.15
- Stochastic Oscillator
- ZLAB 25.91
- RCKT 73.53
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.